Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Position of Executive Chairman to Support Continued Clinical Adoption and Commercial Growth MOUNTAIN VIEW, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences comp ...

Accepted Abstract Highlights Metabolic Response Observations Following Chemotherapeutic Drug-Delivery via the TAMP™ Therapy Platform in Patients Diagnosed with Locally Advanced Pancreatic CancerMOUNTAIN VIEW, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that a clinical data abstract s ...

Core Insights - RenovoRx has established a Medical Advisory Board (MAB) to enhance its TAMP™ therapy platform, focusing on clinical indications with high unmet medical needs [1][2][5] Group 1: Medical Advisory Board Formation - The MAB consists of leading US interventional radiology experts who will provide strategic clinical insights to advance the TAMP therapy platform [2][3] - The MAB will complement the existing Scientific Advisory Board, which focuses on scientific research and clinical program strategy [2] Group 2: Clinical and Market Strategy - The MAB will support ongoing clinical and market strategies and provide insights into potential investigator-initiated trials, which are designed to broaden the application of the TAMP platform [3] - Current trials supported by RenovoRx include studies on borderline resectable and metastatic pancreatic cancer, with potential for expanding targeted indications [3] Group 3: Feedback and Market Introduction - The MAB will also provide feedback to the sales and marketing team as they work to bring RenovoCath to market as a standalone device within its FDA-cleared indications [4] Group 4: RenovoCath Overview - RenovoCath is an FDA-cleared drug-delivery device intended for targeted therapeutic delivery across the arterial wall near tumor sites, aiming to minimize toxicities compared to systemic intravenous therapy [12][13] - The device is also indicated for temporary vessel occlusion in various applications, including arteriography and chemotherapeutic drug infusion [12] Group 5: Commercialization Efforts - RenovoRx is in the early stages of commercializing its TAMP technology and has received its first commercial purchase orders for RenovoCath devices, generating approximately $900,000 in revenue for the first nine months of 2025 [14] - The company is actively exploring further revenue-generating activities to meet anticipated demand [14] Group 6: Ongoing Clinical Trials - RenovoRx is evaluating its intra-arterial gemcitabine product candidate (IAG) in the ongoing Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [15][16] - IAG has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [17]

Core Viewpoint - RenovoRx has appointed Mark Voll as Chief Financial Officer to enhance its leadership team and support the commercialization of its RenovoCath drug-delivery device, marking a significant transition from a clinical stage to a commercial company [1][4]. Group 1: Appointment and Leadership - Mark Voll brings over 30 years of financial leadership experience, having successfully guided high-growth public companies through commercial development [2]. - Voll's role will focus on stockholder communications, budgeting, strategic planning, and finance, which are crucial as RenovoRx commercializes RenovoCath and advances its Phase III TIGeR-PaC clinical trial [3][4]. - CEO Shaun Bagai expressed confidence in Voll's ability to drive sustained commercial execution during this pivotal time for the company [4]. Group 2: Company Overview and Product Information - RenovoRx is a life sciences company focused on developing targeted oncology therapies and commercializing RenovoCath, an FDA-cleared drug-delivery device designed for targeted therapeutic delivery [7]. - RenovoCath is intended for isolating blood flow and delivering fluids to specific sites in the peripheral vascular system, with applications including arteriography and chemotherapeutic drug infusion [6]. - The company has begun commercializing the TAMP therapy platform and RenovoCath, generating approximately $900,000 in revenue from sales in the first nine months of 2025 [8]. Group 3: Clinical Trials and Future Prospects - RenovoRx is evaluating a novel drug-device combination candidate, IAG, in the ongoing Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [9][10]. - IAG has received Orphan Drug Designation for pancreatic and bile duct cancers, providing seven years of market exclusivity upon FDA approval [10].

Core Insights - RenovoRx, Inc. is advancing its innovative targeted oncology therapies through the RenovoCath device, which has received FDA clearance for drug delivery [1][7] - New clinical data will be presented at the 2026 Society of Interventional Oncology Annual Scientific Meeting, focusing on optimizing drug delivery in solid tumors using the TAMP therapy platform [1][2] Clinical Study Findings - The study titled "Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors" aims to simplify intra-arterial pressure measurement during TAMP procedures [2][4] - Real-time pressure measurements provide insights into the mechanics of TAMP procedures, potentially enhancing drug delivery effectiveness [3][4] - The study demonstrates that an external pressure transducer can reliably measure intra-arterial pressure, correlating well with intravascular pressure wire measurements [3] Presentation Details - The clinical data will be presented on February 6, 2026, at 5:45-6:00 PM ET, with the abstract number 303 [4] Company Overview - RenovoRx is focused on developing targeted therapies for high unmet medical needs, utilizing the TAMP therapy platform to minimize toxicities compared to systemic therapies [7] - The company is in the early stages of commercializing the RenovoCath device, having generated approximately $900,000 in revenue from sales in the first nine months of 2025 [8] Product Development - RenovoRx is evaluating a novel drug-device combination candidate, IAG, which involves intra-arterial delivery of gemcitabine via RenovoCath, currently in Phase III trials [9][10] - IAG has received Orphan Drug Designation for pancreatic and bile duct cancers, granting seven years of market exclusivity upon FDA approval [10]

Core Insights - RenovoRx, Inc. announced the acceptance of its abstract submission for the 2026 Society of Interventional Oncology Annual Scientific Meeting, highlighting its innovative targeted oncology therapies and the RenovoCath drug-delivery device [1][6] Group 1: Clinical Study Presentation - The clinical data abstract titled "Real-Time Intravascular Pressure Measurements During Double Balloon Catheter-Mediated Trans-Arterial Micro-Perfusion to Optimize Drug Delivery in Solid Tumors" will be presented by researchers including Dr. Christopher Laing [2] - The study aims to validate a real-time method for intra-arterial pressure monitoring during TAMP procedures using the RenovoCath device, potentially optimizing chemotherapy delivery in challenging tumors [4] Group 2: RenovoCath Overview - RenovoCath is FDA-cleared for isolating blood flow and delivering fluids to specific sites in the peripheral vascular system, with applications in arteriography, preoperative occlusion, and chemotherapeutic drug infusion [5][7] - The device is part of RenovoRx's TAMP therapy platform, designed to enhance targeted therapeutic delivery while minimizing toxicities compared to systemic intravenous therapy [7] Group 3: Commercialization and Financials - RenovoRx is in the early stages of commercializing its TAMP technology and has received its first commercial purchase orders for RenovoCath, generating approximately $900,000 in revenue from sales in the first nine months of 2025 [8] - The company is expanding its customer base, including high-volume National Cancer Institute-designated centers, and is exploring further revenue-generating activities [8] Group 4: Ongoing Clinical Trials - RenovoRx is evaluating its intra-arterial gemcitabine product candidate (IAG) in the Phase III TIGeR-PaC trial, which utilizes the RenovoCath device [9] - IAG has received Orphan Drug Designation for pancreatic and bile duct cancers, providing seven years of market exclusivity upon FDA approval [10]

Core Insights - RenovoRx, Inc. is experiencing commercial momentum with its RenovoCath device being integrated into U.S. cancer centers' oncology treatment programs, enhancing chemotherapy delivery near tumor sites [1][2][5] Group 1: Commercial Adoption - The number of active commercial cancer centers using RenovoCath has increased from five in September 2025 to nine, with notable additions including City of Hope Cancer Center and Moffitt Cancer Center [2] - RenovoRx generated approximately $900,000 in sales revenue through September 2025, indicating a positive trend in commercialization efforts [5][12] Group 2: Clinical Impact - The TAMP therapy platform, enabled by RenovoCath, is highlighted for its potential to improve treatment for difficult-to-treat tumors, such as locally advanced pancreatic cancer [3][10] - The ongoing Phase III TIGeR-PaC trial is evaluating the intra-arterial delivery of gemcitabine via RenovoCath for treating locally advanced pancreatic cancer [10][13] Group 3: Strategic Developments - RenovoRx has established a dedicated commercial team to enhance its go-to-market strategy, which has led to accelerating adoption of RenovoCath [6] - The company is focusing on lessons learned from 2025 to drive revenue growth in 2026, emphasizing physician demand and effective training initiatives [6] Group 4: Future Prospects - The company is exploring further revenue-generating activities and potential partnerships to meet anticipated demand for RenovoCath [12] - RenovoCath has received Orphan Drug Designation for pancreatic cancer, which could provide seven years of market exclusivity upon FDA approval [14]

Core Viewpoint - RenovoRx is making significant progress in its commercial and clinical programs, particularly with its FDA-cleared drug-delivery device, RenovoCath, and its ongoing clinical trials for targeted oncology therapies [1][3]. Commercial Progress - The demand for RenovoCath as a standalone targeted drug-delivery device is increasing, with adoption growing among both new and returning customers, including leading cancer centers [2][10]. - In December 2024, RenovoRx received its first commercial purchase orders for RenovoCath devices, with several customers initiating repeat orders [10]. Clinical Trials - The ongoing Phase III TIGeR-PaC clinical trial is evaluating intra-arterial gemcitabine (IAG) delivered via RenovoCath in patients with locally advanced pancreatic cancer (LAPC) [3][7]. - RenovoRx is also supporting capital-efficient, investigator-initiated trials in borderline resectable and metastatic pancreatic cancer, which may enhance the clinical utility of the TAMP™ therapy platform [3]. Product Information - RenovoCath is designed for the isolation of blood flow and delivery of fluids to selected sites in the peripheral vascular system, and is indicated for temporary vessel occlusion in various applications [5][6]. - The combination product candidate (IAG) is currently under investigation and has not yet been approved for commercial sale, but has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [8].

Core Insights - New pharmacokinetic (PK) and pharmacodynamic data from a sub-study in the Phase III TIGeR-PaC trial supports the efficacy of RenovoRx's TAMP therapy platform for targeted drug delivery in treating locally advanced pancreatic cancer (LAPC) [1][2][4] Group 1: Clinical Data and Findings - The sub-study evaluated intra-arterial gemcitabine (IAG) using the TAMP platform, showing reduced systemic levels of gemcitabine and increased levels of its inactive metabolite compared to intravenous (IV) gemcitabine [3][5] - A direct correlation was found between increased metabolite levels and reduced CA 19-9, a biomarker for chemotherapy response, indicating potential for improved clinical outcomes [3][4] - The study involved 16 patients across six clinical sites, with 11 receiving TAMP and IAG, and five receiving IV gemcitabine, measuring systemic drug exposure and peak plasma concentrations [5] Group 2: Implications for Treatment - The findings suggest that TAMP and IAG may enhance local drug potency while minimizing side effects associated with standard chemotherapy, providing a transformative option for LAPC patients [4][9] - The TAMP therapy platform aims to deliver chemotherapy directly to the tumor site, potentially improving treatment efficiency and effectiveness [4][9] Group 3: Company Overview and Future Directions - RenovoRx is focused on developing targeted oncology therapies and has commercialized the RenovoCath device, which is FDA-cleared for drug delivery [9][10] - The company is actively commercializing its TAMP technology and has generated approximately $900,000 in revenue from RenovoCath sales in the first nine months of 2025 [10] - RenovoRx is also exploring further revenue-generating activities and expanding its customer base among high-volume cancer centers [10]

Core Viewpoint - RenovoRx, Inc. is actively commercializing its innovative targeted oncology therapies, particularly focusing on the RenovoCath device, which has shown growing clinical demand and market traction [1][2][6] Group 1: Company Updates - CEO Shaun Bagai will present at the iAccess Alpha Virtual Best Ideas Winter Investment Conference on December 9, 2025, to discuss the company's commercial efforts and market traction [1][4] - Year-to-date revenue for RenovoRx reached approximately $900,000 by the end of September 30, 2025, indicating progress in its commercialization efforts [2][7] - The company has received its first commercial purchase orders for RenovoCath devices and has seen repeat orders from several customers, including high-volume National Cancer Institute-designated centers [7] Group 2: Clinical Research and Development - The ongoing Phase III TIGeR-PaC clinical trial is evaluating intra-arterial gemcitabine delivered via RenovoCath in patients with locally advanced pancreatic cancer [3][8] - RenovoRx is also conducting a post-marketing registry study to capture real-world data on the safety and effectiveness of RenovoCath in patients with solid tumors [3] - The company supports investigator-initiated trials in borderline resectable and oligometastatic pancreatic cancer, which may broaden the application of its TAMP™ therapy platform [3][6] Group 3: Product Information - RenovoCath is an FDA-cleared drug-delivery device designed for targeted therapeutic delivery, aiming to minimize toxicities compared to systemic intravenous therapy [5][6] - The device is indicated for temporary vessel occlusion and the delivery of fluids, including therapeutic agents, to specific sites in the peripheral vascular system [5][9] - RenovoCath with gemcitabine has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, providing seven years of market exclusivity upon FDA approval [10]